Green Leaf Pharmaceuticals (02186.HK) has granted BeHua exclusive commercialization rights for three long-acting injectable antipsychotic products in mainland China.

Zhixin Finance APP News, China Green Leaf Pharmaceuticals (02186.HK) announced that some of its subsidiary companies have signed a cooperation agreement with a subsidiary of Jiangsu Enhua Pharmaceutical Co., Ltd., Jiangsu Enhua Hexin Pharmaceutical Marketing Co., Ltd. (Enhua), granting Enhua exclusive commercialization rights for three long-acting injectable antipsychotic products in mainland China. The three products are Rexulti (Aripiprazole Microspheres for Injection), Rebilin (Paliperidone Palmitate Injectable Solution), and Mejiri (Paliperidone Palmitate Injectable Solution), all used for the treatment of schizophrenia.